Genexine Competitors and Similar CompaniesClear all
Genexine's competitors and similar companies include Travere Therapeutics, JCR Pharmaceuticals, GBT (Global Blood Therapeutics) and Kamada Pharmaceuticals.
 Genexine Genexine is a biotechnology company focused on the development and commercialization of immunotherapeutics and long-acting biologics. |  Travere Therapeutics Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. |  JCR Pharmaceuticals JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products. |  GBT (Global Blood Therapeutics) GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. |  Kamada Pharmaceuticals Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications. | |
Founding Date | Founding Date 1999 | Founding Date 2011 | Founding Date 1975 | Founding Date 2012 | Founding Date 1990 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Seongnam-si, KR HQ New York, US | Locations San Diego, US HQ Dublin, IE | Locations Ashiya, JP HQ Kobe, JP Kobe, JP Kobe, JP Kobe, JP | Locations South San Francisco, US HQ Paris, FR Berlin, DE Baar, CH London, GB | Locations Rehovot, IL HQ Beit Kama, IL |
Employees | Employees 86 | Employees 46293% increase | Employees 934 | Employees 352106% increase | Employees 420 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.4 b | Valuation ($) 533.9 m | Valuation ($) 4.4 b | Valuation ($) 317 m |
Financial | |||||
Revenue (est.) | Revenue (est.) ₩4.6b (FY, 2025) | Revenue (est.) $490.7m (FY, 2025) | Revenue (est.) ¥33.1b (FY, 2025) | Revenue (est.) $194.7m (FY, 2021) | Revenue (est.) $180.5m (FY, 2025) |
Cost of goods | Cost of goods (₩503.7m) (FY, 2025) | Cost of goods $10.3m (FY, 2025) | Cost of goods ¥8b (FY, 2025) | Cost of goods $3.3m (FY, 2021) | Cost of goods $72.1m (FY, 2025) |
Gross profit | Gross profit ₩7.8b (FY, 2025) | Gross profit $480.4m (FY, 2025) | Gross profit ¥25.1b (FY, 2025) | Gross profit N/A | Gross profit $108.4m (FY, 2025) |
Net income | Net income (₩27.2b) (FY, 2025) | Net income ($25.5m) (FY, 2025) | Net income (¥4.7b) (FY, 2025) | Net income ($303.1m) (FY, 2021) | Net income $20.2m (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 25m | Total funding raised N/A | Total funding raised $ 88.7m | Total funding raised $ 90m |
For sources of this data, please see the company profile
View Company Profiles
Travere Therapeutics
HQ
San Diego, US
Employees
462
Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.
View companyJCR Pharmaceuticals
HQ
Ashiya, JP
Employees
934
JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products.
View companyGBT (Global Blood Therapeutics)
HQ
South San Francisco, US
Employees
352
GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need.
View companyKamada Pharmaceuticals
HQ
Rehovot, IL
Employees
420
Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications.
View company